The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors

Summary

Several small case-control studies have investigated whether factor V Leiden (FVL) is a risk factor for retinal vein occlusion (RVO) and generated conflicting data. To clarify this question we performed a large two-centre case-control study and a meta-analysis of published studies. Two hundred seven consecutive patients with RVO and a control group of 150 subjects were screened between 1996 and 2006. A systematic meta-analysis was done combining our study with further 17 published European case-control studies. APC resistance was detected in 16 out of 207 (7.7%) patients and eight out of 150 (5.3%) controls. The odds ratio (OR) estimated was 1.49 with a (non-significant) 95% confidence interval (CI) of 0.62–3.57. The meta-analysis including 18 studies with a total of 1,748 patients and 2,716 controls showed a significantly higher prevalence of FVL in patients with RVO compared to healthy controls (combined OR 1.66; 95% CI 1.19–2.32). All single studies combined in the meta-analysis were too small to reliably detect the effect individually. This explains the seemingly contradictory data in the literature. In conclusion, the prevalence of APC resistance (and FVL) is increased in patients with RVO compared to controls, but the effect is only moderate. Therefore, there is no indication for general screening of factor V mutation in all patients with RVO. We recommend this test to be performed in patients older than 50 years with an additional history of thromboembolic event and in younger patients without general risk factors like hypertension.

Keywords

Retinal vein occlusion - factor V Leiden - APC resistance - activated protein C - meta-analysis

• References

• 1 The Eye Disease Case-Control Study Group: Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114: 545-554.
• 2 Weger M, Renner W, Steinbrugger I. et al. Role of thrombophilic gene polymorphisms in branch retinal vein occlusion. Ophthalmology 2005; 112: 1910-1915.
• 3 Cahill MT, Stinnett SS, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol 2003; 136: 1136-1150.
• 4 Janssen MC, de Heijer M, Cruysberg JR. et al. Retinal vein occlsuion: a form of venous thrombosis or a complication of atherosclerosis?. Thromb Haemost 2005; 93: 1021-1026.
• 5 Leoncini G, Bruzzese D, Signorello MG. et al. Platelet activation by collagen is increased in retinal vein occlusion. Thromb Haemost. 2007; 97: 218-227.
• 6 Fateh-Moghadam S, Gawaz M. Retinal vein occlusion disease and platelet activation: will antiplatelet therapy be a promising therapeutic strategy for patients with retinal vein occlusion disease in the future?. Thromb Haemost 2007; 97: 169-170.
• 7 Lippi G, Franchini M, Targher G. Platelets and lipoprotein( a) in retinal vein occlusion: mutual targets for aspirin therapy. Thromb Haemost 2007; 97: 1059-1060.
• 8 Gumus K, Kadayifcilar S, Eldem B. et al. Is elevated level of soluble endothelial protein C receptor a new risk factor for retinal vein occlusion?. Clin Experiment Ophthalmol 2006; 34: 305-311.
• 9 Arsene S, Delahousse B, Regina S. et al. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005; 94: 101-106.
• 10 Albisinni R, Coppola A, Loffredo M. et al. Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost 1998; 80: 702-703.
• 11 Marcucci R, Bertini L, Giusti B. et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86: 772-776.
• 12 Larsson J, Hillarp A, Olafsdottir E. et al. Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmol Scand 1999; 77: 634-637.
• 13 Greiner K, Peetz D, Winkgen A. et al. Genetic thrombophilia in patients with retinal vascular occlusion. Int Ophthalmol. 1999; 23: 155-160.
• 14 Gottlieb JL, Blice JP, Mestichelli B. et al. Activated protein C resistance, factor V Leiden, and central retinal vein occlusion in young adults. Arch Ophthalmol 1998; 116: 577-579.
• 15 Demirci FY, Güney DB, Akarcay K. et al. Prevalence of factor V Leiden in patients with retinal vein occlusion. Acta Ophthalmol Scand 1999; 77: 631-633.
• 16 Cruciani F, Moramarco A, Curto T. et al. MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion. Clin Ter 2003; 154: 299-303.
• 17 Kalayci D, Gürgey A, Güven D. et al. Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. Acta Ophthalmol Scand 1999; 77: 622-624.
• 18 Linna T, Ylikorkala A, Kontula K. et al. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997; 77: 214-216.
• 19 Kuhli C, Hattenbach LO, Scharrer I. et al. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 163-168.
• 20 Larsson J, Sellman A, Bauer B. Activated protein C resistance in patients with central retinal vein occlusion. Br J Ophthalmol 1997; 81: 832-834.
• 21 Aras S, Yilmaz G, Alpas I. et al. Retinal vein occlusion and factor V Leiden and prothrombin 20210 G:A mutations. Eur J Ophthalmol 2001; 11: 351-355.
• 22 Bombeli T, Basic A, Fehr J. Prevalence of hereditary thrombophilia in patients with thrombosis in different venous systems. Am J Hematol 2002; 70: 126-132.
• 23 Marcucci R, Giusti B, Betti I. et al. Genetic determinants of fasting and post-methionine hyperhomocysteinemia in patients with retinal vein occlusion. Thromb Res 2003; 110: 7-12.
• 24 Gori AM, Marcucci R, Fatini C. et al. Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost 2004; 92: 54-60.
• 25 Egger M, Smith GD, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-634.
• 26 Ihaka R, Gentleman RR. A language for data analysis and graphics. J Comp Graph Stat 1996; 5: 299-314.
• 27 Bertina RM, Koelemann BPC, Koster T. et al. Mutation in blood coagulations factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
• 28 Segers K, Dahlbäck B, Nicolaes GA. Coagulation factor V and thrombophilia: background and mechanisms. Thromb Haemost 2007; 98: 530-542.
• 29 Dahlbäck B, Carlsson M, Svensson PJ. Familiar thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: predilection of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
• 30 Trossaert M, Conard J, Horellou MH. et al. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant. Thromb Haemost 1996; 75: 521-522.
• 31 Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 1997; 77: 332-335.